drugset / Trial / NCT01789957

Extension Study for 2993-112

NCT01789957

Phase 3 Completed 225 enrolled AstraZeneca
NaSingle-groupOpen-labelTreatment

Summary

This multicenter, open-label extension study of Protocol 2993-112 is designed to assess long-term glucose control as measured by HbA1c (glycosylated hemoglobin) and to evaluate long-term safety and tolerability in subjects treated with metformin who receive subcutaneously injected AC2993 (10 mcg) administered twice daily. Subjects completing Protocol 2993-112 are eligible to enroll.

Timeline

Start
2002-09
Primary completion
2004-06
Completion
2004-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Exenatide Peptide 10 ug Subcutaneous